Y Intercept Hong Kong Ltd Has $604,000 Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Y Intercept Hong Kong Ltd cut its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 34.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,905 shares of the biopharmaceutical company’s stock after selling 17,639 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in ACADIA Pharmaceuticals were worth $604,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. R Squared Ltd acquired a new position in ACADIA Pharmaceuticals in the 4th quarter valued at $47,000. Quest Partners LLC grew its stake in ACADIA Pharmaceuticals by 42.3% in the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 1,047 shares during the last quarter. KBC Group NV grew its stake in ACADIA Pharmaceuticals by 67.0% in the 4th quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 2,044 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in ACADIA Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 1,066 shares during the last quarter. Finally, PDT Partners LLC acquired a new stake in ACADIA Pharmaceuticals in the 3rd quarter worth $203,000. 96.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on ACAD shares. StockNews.com lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. Guggenheim lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $23.00 to $20.00 in a research report on Friday, January 3rd. Needham & Company LLC restated a “buy” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday. HC Wainwright restated a “buy” rating and issued a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday. Nine equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

ACADIA Pharmaceuticals Stock Up 1.3 %

Shares of ACAD stock opened at $19.60 on Friday. ACADIA Pharmaceuticals Inc. has a 12-month low of $14.15 and a 12-month high of $24.53. The company has a market capitalization of $3.26 billion, a P/E ratio of 25.13 and a beta of 0.37. The firm has a 50-day moving average price of $18.42 and a 200 day moving average price of $16.85.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.